Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
Elaine S. DeMeyer, MSN, RN, AOCN®, BMTCN®, is the owner of beyond Oncology Education, LLC and has been a nurse entrepreneur for more than two decades. Elaine leverages her healthcare background along with creativity, business knowledge, and collaborative relationships.
Her mission through beyond Oncology is: To improve patient care by empowering oncology professionals with the tools and resources to change practice.
Articles by Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
Learn how oncology nurses can assess for CRS and ICANS, which are the main side effects of CAR-T and BiTE therapies.
Oncology nurses must understand how these therapies are similar but different regarding therapy-specific side effects.
Oncology nurses need to understand this complication to identify patients at high risk for steroid-induced hyperglycemia.
This common complication occurs in up to two-thirds of patients receiving steroids.
Oncology nurses have a central role in glycemia control, beginning with a clear assessment of glucose blood levels.
The Rios study revealed significant racial disparities in acute GVHD outcomes.
Learn how oncology nurses can help address disparities and bridge gaps to improve GVHD outcomes.
Oncology nurses may be the first to identify the classic triad of hyperviscosity syndrome symptoms.
Almost all patients with multiple myeloma at some point will develop bone disease—the “B” in CRAB.
Oncology nurses are integral to the success of ECP, as they provide ongoing education and psychosocial support to patients.
Before axatilimab, targeting the CSF-1R pathway was not previously studied in cGVHD.
New research and therapeutic approaches are challenging long-held beliefs about this type of graft.
Understanding critical symptoms in the “CRAB” acronym can enable oncology nurses to educate patients and caregivers.
Up to 50% of patients have renal insufficiency at the time of multiple myeloma diagnosis.
It's critical for oncology nurses to encourage these patients to monitor their blood pressure at home.
Renal toxicity occurs in approximately 75% of all patients who receive allogeneic stem cell transplants.
Learn how oncology nurses can address the challenges associated with early detection, diagnosis, and management.
It's critical for oncology nurses understand and recognize the 3 atypical lung cGVHD conditions.
Oncology nurses must familiarize themselves with CNS and PNS cGVHD to improve patient outcomes.
With better understanding of CNS cGVHD, oncology nurses can help ensure early recognition and reporting.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.